- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03814642
Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants
October 18, 2019 updated by: HK inno.N Corporation
A Randomized, Open-label, Three-period, Multiple Dosing Crossover Clinical Trial to Evaluate the Influence of Tegoprazan on the Pharmacodynamics of Clopidogrel According to CYP2C19 Genotypes in Healthy Male Volunteers
This study aims to evaluate the influence of tegoprazan on the pharmacodynamics of clopidogrel according to CYP2C19 genotypes following co-administration of tegoprazan and clopidogrel in healthy male volunteers.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Evaluation Criteria:
- Pharmacodynamic assessments using P2Y12 assay
- Safety assessments with adverse event monitoring including subjective/objective symptoms, physical examination, vital signs, electrocardiogram, and laboratory test
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital, Clinical Trial Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years to 48 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy adult males aged ≥ 19 years and ≤ 50 years on the date of the written informed consent
- Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 18.0 kg/m2 and ≤ 27.0 kg/m2 at the time of screening
- Helicobacter pylori negative
- Voluntarily decided to participate in the study and provided written informed consent before any screening procedure
- Judged by the investigator to be eligible for this study based on physical examination, laboratory test, inquiry, etc.
Exclusion Criteria:
- Has a history of or currently has clinically significant liver, kidney, nervous system, respiratory system, endocrine system, blood, cardiovascular system, urinary system, or psychiatric disease or tumor
- Has a history of or currently has gastrointestinal disorder (gastrointestinal ulcer, gastritis, stomach cramps, gastroesophageal reflux disease, Crohn's disease, etc.) that may influence the safety and pharmacodynamic assessments of the investigational product
- Has a history of gastrointestinal surgery (except simple appendectomy and hernia surgery)
- Hypersensitivity to drugs including the ingredients of the investigational product and other drugs (aspirin, antibiotics, etc.) or a history of clinically significant hypersensitivity
- Positive serological test including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
- Blood total bilirubin, AST (GOT), and ALT (GPT) levels greater than 1.5x of the upper limit of normal range at screening
- Platelet, PT and aPTT levels outside the upper/lower limit of normal range by 10% at screening
- P2Y12 Reaction Unit (PRU) by P2Y12 assay outside the upper/lower limit of normal range by 10% at screening
- *17 allele by CYP2C19 genotyping (Ultrarapid metabolizer)
- Systolic blood pressure < 90 mmHg or > 140 mmHg, diastolic blood pressure < 50 mmHg or > 95 mmHg, or pulse rate < 45 beats/minute or > 100 beats/minute when vital signs are measured in sitting position after resting for at least 5 minutes during screening
- QTc > 450 msec, PR interval > 200 msec, QRS interval > 120 msec, and other clinically significant findings on electrocardiogram at screening
- Has a history of or positive urine screening for drug abuse
- Administration of any prescription drugs or herbal medicine within 2 weeks prior to the expected date of the first dose, or administration of any over-the-counter (OTC) drug, health functional food or vitamin within 1 week prior to the expected date of the first dose (However, can participate in the study if otherwise decided eligible by the investigator)
- Participation in other clinical study or bioequivalence study to receive an investigational product within 3 months prior to the expected date of the first dose
- Donation of whole blood within 2 months or apheresis/receipt of blood transfusion within 1 month prior to the expected date of the first dose
- Excessive caffeine intake (> 5 units/day) or persistent alcohol intake (> 21 units/week, 1 unit = 10 g of pure alcohol), or inability to abstain from drinking during hospitalization period
- Smoking for more than 3 months prior to the study or inability to cease smoking throughout the study
- Inability to refrain from grapefruit-containing food from 24 hours before admission to discharge
- Inability to refrain from caffeine-containing food (coffee, tea (black tea, green tea, etc.), carbonated drink, coffee-flavored milk, nutritional tonic, etc.) from 24 hours before admission to discharge
- Inability to use a medically acceptable method of contraception throughout the study. Medically acceptable methods of contraception include use of intrauterine device with established failure rate of contraception by spouse (or partner), concomitant use of barrier method (for male or for female) and spermicide, or surgical procedure on subject himself or his partner (vasectomy, tubal resection/ligation, hysterectomy)
- Considered ineligible to participate in the study by the investigator based on laboratory test results or other reasons
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Clopidogrel 75 mg
Oral administration of clopidogrel 75 mg tablet once daily for 7 days
|
Clopidogrel 75 mg tablet
Other Names:
|
Experimental: Clopidogrel 75 mg + Tegoprazan 50 mg
Oral administration of clopidogrel 75 mg tablet and tegoprazan 50 mg tablet once daily for 7 days
|
Tegoprazan 50 mg tablet
Other Names:
Clopidogrel 75 mg tablet
Other Names:
|
Experimental: Clopidogrel 75 mg + Esomeprazole 20 mg
Oral administration of clopidogrel 75 mg tablet and esomeprazole 20 mg tablet once daily for 7 days
|
Clopidogrel 75 mg tablet
Other Names:
Esomeprazole 20 mg tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in P2Y12 Reaction Unit (PRU) from baseline
Time Frame: Pre-dose(0h) on days 1, 3, 5, and 8 in each period
|
Pharmacodynamic blood sampling to measure PRU using VerifyNow® system
|
Pre-dose(0h) on days 1, 3, 5, and 8 in each period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: In-Jin Jang, Seoul National University Hospital, Dept. of Clinical Pharmacology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 21, 2019
Primary Completion (Actual)
July 22, 2019
Study Completion (Actual)
July 22, 2019
Study Registration Dates
First Submitted
January 20, 2019
First Submitted That Met QC Criteria
January 20, 2019
First Posted (Actual)
January 24, 2019
Study Record Updates
Last Update Posted (Actual)
October 21, 2019
Last Update Submitted That Met QC Criteria
October 18, 2019
Last Verified
October 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Purinergic P2Y Receptor Antagonists
- Purinergic P2 Receptor Antagonists
- Purinergic Antagonists
- Purinergic Agents
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Clopidogrel
- Esomeprazole
Other Study ID Numbers
- CJ_APA_110
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Tegoprazan 50 mg
-
HK inno.N CorporationCompleted
-
HK inno.N CorporationRecruitingExploratory Study to Standard Triple Therapy With Tegoprazan(by Dose) in H. Pylori Positive PatientsHelicobacter Pylori InfectionKorea, Republic of
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
HK inno.N CorporationCompletedHealthyKorea, Republic of
-
Zydus Lifesciences LimitedActive, not recruitingAmyotrophic Lateral SclerosisIndia
-
HK inno.N CorporationCompletedPharmacodynamics | Healthy Male VolunteersKorea, Republic of
-
HK inno.N CorporationUnknownHealthyKorea, Republic of
-
ViiV HealthcareGlaxoSmithKline; Janssen PharmaceuticalsCompletedInfection, Human Immunodeficiency VirusUnited States
-
Alcon ResearchCompletedNeovascular Age-Related Macular Degeneration
-
Sprout Pharmaceuticals, IncCompletedSexual Dysfunctions, PsychologicalAustria, Belgium, Czech Republic, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom